688336 Stock Overview
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.77 |
| 52 Week High | CN¥26.78 |
| 52 Week Low | CN¥15.22 |
| Beta | 0.39 |
| 1 Month Change | -8.84% |
| 3 Month Change | 19.42% |
| 1 Year Change | -0.046% |
| 3 Year Change | 21.76% |
| 5 Year Change | n/a |
| Change since IPO | -59.76% |
Recent News & Updates
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Has A Rock Solid Balance Sheet
Nov 19
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29There's Reason For Concern Over Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) Massive 30% Price Jump
Oct 01Recent updates
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Has A Rock Solid Balance Sheet
Nov 19Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29There's Reason For Concern Over Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) Massive 30% Price Jump
Oct 01What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You
Jul 25Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
Jun 20If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity
May 24We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04Shareholder Returns
| 688336 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -4.9% | -3.5% |
| 1Y | -0.05% | -17.6% | 10.9% |
Return vs Industry: 688336 exceeded the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 688336 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688336 volatility | |
|---|---|
| 688336 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688336 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688336's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 964 | n/a | www.3s-guojian.com |
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an initututab for injection; and Xenipax, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation, as well as used in conjunction with conventional immunosuppression regimens to increase the survival rate of transplanted organs and enhance patients' quality of life. The company is also developing products for autoimmune, oncology, ophthalmological, and other diseases.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Fundamentals Summary
| 688336 fundamental statistics | |
|---|---|
| Market cap | CN¥13.33b |
| Earnings (TTM) | CN¥363.75m |
| Revenue (TTM) | CN¥1.22b |
36.9x
P/E Ratio11.0x
P/S RatioIs 688336 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688336 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.22b |
| Cost of Revenue | CN¥286.11m |
| Gross Profit | CN¥936.73m |
| Other Expenses | CN¥572.98m |
| Earnings | CN¥363.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 76.60% |
| Net Profit Margin | 29.75% |
| Debt/Equity Ratio | 1.0% |
How did 688336 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield14%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Dai | Huatai Research |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |
| Ban Wang | Minsheng Securities Co. |